LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin
Author:
- 15 December 2010
- journal article
- review article
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 23 (3) , 193-200
Abstract
LX‐1031 is an oral, small molecule tryptophan 5‐hydroxylase (TPH) inhibitor that reduces serotonin (5‐HT) synthesis peripherally. It has potential for illnesses characterized by excess 5‐HT, such as diarrhea‐predominant irritable bowel syndrome (IBS‐D) and carcinoid diarrhea. In vitro, inhibition of TPH1 occurred in 10−8–10−7 mol L−1 range. In vivo in rodents, LX‐1031 has no effect on brain 5‐HT while dose‐dependently reducing 5‐HT, particularly in the small bowel. After oral LX1031 in humans, systemic exposure is very low, plasma concentrations are linear in dose range 250–750 mg q.i.d.; the median T1/2 for elimination is ∼20 h, and repeat administration for 14 days doubles Cmax. In ascending‐single‐dose and multiple‐dose (14 days) trials in healthy volunteers, LX‐1031, 2–4 g day−1 significantly reduced urinary 5‐hydroxyindoleacetic acid (5‐HIAA) starting by Day 5, and persisting over the 14 day exposure. There are no dose‐limiting toxicities in healthy subjects or remarkable adverse effects in clinical trials to date. Over a 28‐day treatment period, LX‐1031 was associated with improved weekly global scores (2/4 weeks) and improved stool consistency with lower urinary 5‐HIAA excretion. LX‐1031 appears promising for chronic diarrhea associated with increased 5‐HT expression including IBS‐D. Optimal doses, efficacy and safety in IBS clinical trials need to be fully elucidated; low systemic exposure, selectivity for TPH1 over TPH2, and lack of effect on brain 5‐HT in several species suggest that LX‐1031 is unlikely to cause affective disorders.Keywords
This publication has 53 references indexed in Scilit:
- Serotonin Signaling Is Altered in Irritable Bowel Syndrome With Diarrhea but Not in Functional Dyspepsia in Pediatric Age PatientsGastroenterology, 2010
- Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosisNature Medicine, 2010
- Effects of Chenodeoxycholate and a Bile Acid Sequestrant, Colesevelam, on Intestinal Transit and Bowel FunctionClinical Gastroenterology and Hepatology, 2010
- Effects of Velusetrag (TD‐5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipationNeurogastroenterology & Motility, 2009
- Review article: new receptor targets for medical therapy in irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2009
- Challenges to the Therapeutic Pipeline for Irritable Bowel Syndrome: End Points and Regulatory HurdlesGastroenterology, 2008
- Effects of 5-Hydroxytryptamine (Serotonin) Type 3 Antagonists on Symptom Relief and Constipation in Nonconstipated Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsClinical Gastroenterology and Hepatology, 2008
- Meta‐analysis: a functional polymorphism in the gene encoding for activity of the serotonin transporter protein is not associated with the irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2007
- Alterations in Expression of p11 and SERT in Mucosal Biopsy Specimens of Patients With Irritable Bowel SyndromeGastroenterology, 2007
- Treatment of the Malignant Carcinoid SyndromeNew England Journal of Medicine, 1986